drugset / Trial / NCT01045564
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
Phase 2
Withdrawn
GlaxoSmithKline
United States Department of Health and Human Services, Center for Disease Control and Prevention, National Institutes of Health, Department of Defense · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to characterize the immunogenicity and safety of 3 doses of GSK's avian flu vaccine GSK 1557484A given at different time intervals to adults aged 18 years or greater who are at increased occupational risk of H5N1 exposure.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-02
- Completion
- 2013-02
Outcome
Outcome not reported
Stopped: “Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK1557484A | Vaccine | — | Intramuscular |